# EDGAR Filing Document

**Accession Number:** 0001756594
**File Stem:** 0001171843-25-007102
**Filing Date:** 2025-11
**Character Count:** 5293
**Document Hash:** 4dfc241e1ae2ed1182939538ae12e799
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-007102.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001171843-25-007102

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251106

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inventiva S.A.
- **CENTRAL INDEX KEY:** 0001756594
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39374
- **FILM NUMBER:** 251459413

**BUSINESS ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121
- **BUSINESS PHONE:** 33380447500

**MAIL ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2025**

Commission File Number: **001-39374**

**Inventiva S.A.**

(Translation of registrant's name into English)

**50 rue de Dijon**

 **21121 Daix France**

 **+33 3 80 44 75 00**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

------

On November 6, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[(c) Exhibit 99.1. Press release dated November 6, 2025](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;Inventiva S.A.&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: November 6, 2025 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Andrew Obenshain&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Andrew Obenshain |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Statement of total voting rights and shares forming the company's share capital as October 20, 2025**

 ***Article R. 22-10-23 of the French Commercial Code***

Market : Euronext Paris

ISIN code / Mnemo : FR0013233012 / IVA

Web site : <u>www</u><u>.</u><u>i</u><u>n</u><u>v</u><u>e</u><u>n</u><u>t</u><u>i</u><u>v</u><u>a</u><u>p</u><u>ha</u><u>r</u><u>m</u><u>a.</u><u>c</u><u>om</u>

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;<br>Date | &nbsp;&nbsp;&nbsp;&nbsp; Number of Shares Outstanding | &nbsp;&nbsp;&nbsp;&nbsp;<br>Total voting rights, <br>gross <sup>(1</sup><sup>)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;<br>Total voting rights, <br>net <sup>(</sup><sup>2</sup><sup>)</sup> |
| October 20<sup>th</sup>, 2025 | 145 951 274 | 158 653 570 | 158 594 019 |

---

*(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.*

*(2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed.*

**About Inventiva** 

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://inventivapharma.com/

**Contacts** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Inventiva**<br>Pascaline Clerc<br>EVP, Strategy and Corporate Affairs<br>media@inventivapharma.com<br>+1 202 499 8937 | &nbsp;&nbsp; **ICR Healthcare**<br>Media Relations <br>Alexis Feinberg <br>inventivapr@icrhealthcare.com<br>+1 203 939 2225 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **ICR Healthcare**<br>Investor relations<br>Patricia L. Bank<br>patti.bank@icrhealthcare.com <br>+1 415 513 1284 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Attachment**

* 
 Inventiva - PR - number of shares and voting rights as at October 20 2025 - EN- 11 06 2025 (https://ml-eu.globenewswire.com/Resource/Download/b05f77e6-f12a-4196-a963-932e47faada2)